If you or a loved one has lung cancer, you may be looking into different treatment options. One new medicine you may hear about is Ensacove (ensartinib). In December 2024, the FDA approved Ensacove as ...

Is Alunbrig Right for Me? Your health care provider will consider what type of lung cancer you have and whether it has spread to help choose the right treatment for you. Alunbrig is used for NSCLC ...

Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people who ...

Alecensa reduced death risk by 22% compared to Xalkori in advanced ALK-positive NSCLC, with a median OS of 81.1 months versus 54.2 months. The study was not powered for OS, resulting in ...

Ensartinib offers improved progression-free survival for ALK-positive NSCLC compared with crizotinib, with a median PFS of 25.8 months vs 12.7 months. Adverse events with ensartinib are mostly mild, ...

– ALINA data demonstrate Alecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the ...

Logan Terry, who has stage 4 ALK-positive lung cancer, encouraged patients with cancer to keep living fully after diagnosis and not be defined by fear or bitterness. Patients who are newly diagnosed ...

A new pill has kept lung-cancer patients free of the disease after surgery in a major clinical trial, offering a fresh option for a specific, hard-to-treat subgroup. According to ...

Adults in England and Wales with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) will soon have access to a new first-line treatment. The National Institute for ...

The National Institute for Health and Care Excellence (NICE) has recommended alectinib (Alecensa) for ALK-positive non-small cell lung cancer following surgery to reduce recurrence risk. Around 100 ...

Quantifying clinical harm and financial waste from failure to deploy personalized medicine for patients with metastatic non-small cell lung cancer in the United States. This is an ASCO Meeting ...

The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the agency announced on Wednesday.